Frontotemporal Dementia
Frontotemporal Dementia Market

Frontotemporal Dementia

FTD is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behaviour, and language. There are three types of frontotemporal disorders (FTD): behavioural variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and movement disorders.


Frontotemporal Dementia Epidemiology Segmentation in the 7MM


  • Total Diagnosed Prevalent Cases
  • Type-specific Diagnosed Prevalent Cases
  • Gene-specific Diagnosed Prevalent Cases


Frontotemporal Dementia Epidemiological Insights Observed in the 7MM (2021)

The total number of incident cases of Frontotemporal Dementia observed in the 7MM was observed to be 128K in the year 2021

The highest diagnosed Frontotemporal Dementia population accounting for 59K cases, was found in the United States, followed by EU5 (57K) and Japan (12K) in the year 2021. 


Frontotemporal Dementia Market Insight

The market size of Frontotemporal Dementia in the 7MM was found to be approximately USD 92 million in 2021


Frontotemporal Dementia Market Strengths

The absence of a marketed drug for Frontotemporal Dementia probably act as a strength for emerging drugs to lead the market once approved.


Frontotemporal Dementia Market Opportunities

Renewed interest in Frontotemporal Dementia research gives hope for future advancements that aim to increase diagnostic capabilities and expand treatment options through novel therapeutic targets.


Frontotemporal Dementia Emerging Drugs and Key Companies


  • Latozinemab (AL001): Alector Inc.
  • OBP-601: Transposon Therapeutics, Inc/Oncolys BioPharma Inc
  • DNL593: Denali Therapeutics Inc
  • BFT02: Passage Bio, Inc
  • PR006: Prevail Therapeutics
  • WVE-004: Wave Life Sciences